Switch to
More onapp

Dr. Lal PathLabs Ltd

LALPATHLAB
Health CareHospitals & Diagnostic Centres
MidcapWith a market cap of ₹17,012 cr, stock is ranked 247
Moderate RiskStock is 2.35x as volatile as Nifty
2,012.3540.15 (-1.96%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CareHospitals & Diagnostic Centres
MidcapWith a market cap of ₹17,012 cr, stock is ranked 247
Moderate RiskStock is 2.35x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
49.33
PB RatioPB Ratio
11.02
Dividend YieldDiv. Yield
0.59%
Sector PESector PE
33.90
Sector PBSector PB
4.15
Sector Div YldSctr Div Yld
0.93%

Forecast & RatingsDetailed Forecast 

25%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Dr Lal Pathlabs Private Limited is headquartered in Gurgaon, Haryana, India and is a medical laboratory operator.

Brands

Dr. Lal PathLabs

Diagnostic and healthcare services by Dr. Lal PathLabs Ltd

Investor PresentationView older 

Nov 8, 2022

PDF
View Older Presentations

Brands

Dr. Lal PathLabs

Diagnostic and healthcare services by Dr. Lal PathLabs Ltd

Financial TrendFinancial statements 

20192020202120221.251.391.632.140.200.230.290.34
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Acquisition 
Announced OnJan 30, 2023

Please take note that the Board of Directors of PathLabs Unifiers Private Limited ( PUPL ) (a Wholly Owned Subsidiary of the Company) in their meeting on January 30, 2023 approved the acquisition of further 10% equity stake in its Subsidiary Company i.e. APRL PathLabs Private Limited ( APRL ). | Download

Please take note that the Board of Directors of PathLabs Unifiers Private Limited ( PUPL ) (a Wholly Owned Subsidiary of the Company) in their meeting on January 30, 2023 approved the acquisition of further 10% equity stake in its Subsidiary Company i.e. APRL PathLabs Private Limited ( APRL ). | Download

Analysts/Institutional Investor Meet/Con. Call Updates 
Announced OnJan 27, 2023

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the invite of the Conference Call for Investors/Analysts to be held on Thursday, February 02, 2023 at 05:00 pm IST to discuss the financial and operating performance for Q3 & 9M FY23. | Download

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the invite of the Conference Call for Investors/Analysts to be held on Thursday, February 02, 2023 at 05:00 pm IST to discuss the financial and operating performance for Q3 & 9M FY23. | Download

Cash Dividend 
Ex. DateAug 5, 2022

Interim • Div/Share: ₹ 6

See all events